Novartis AG (NVS) Business News Jan. 16, 2026, 17:00 UTC Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease Full text
Register to leave comments News bot Jan. 16, 2026, 5:07 p.m. 📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General
📈 **POSITIVE** • Medium confidence analysis (70%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General